Dyrk1a inhibition with the Novel Compound DYR533: A Cross-Disease Therapeutic Strategy Targeting Amyloidosis, Tau...

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) and related dementias (ADRDs) are increasing, with current therapies limited against tau pathology and neuroinflammation.
• Dual-specificity tyrosine-phosphorylation-regulated kinase 1a (Dyrk1a) is implicated in phosphorylating tau and amyloid precursor protein, and regulating inflammatory signaling, making it a key target in ADRDs.

Purpose of the Study:

• To investigate the role of Dyrk1a in ADRDs and evaluate a novel Dyrk1a inhibitor, DYR533, as a potential therapeutic strategy.

Main Methods:

• Measured brain Dyrk1a protein levels across various ADRDs.
• Developed and administered DYR533, a selective, orally bioavailable, brain-penetrant Dyrk1a inhibitor.
• Assessed DYR533's effects on tau pathology, neuroinflammation, amyloidosis, and behavioral deficits in three established mouse models of ADRD.

Main Results:

• Brain Dyrk1a protein levels were consistently elevated in ADRDs, including AD, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.
• DYR533 treatment reduced pathological tau hyperphosphorylation, attenuated neuroinflammation, and ameliorated amyloidosis in mouse models.
• DYR533 administration improved anxiety-like behavior and spatial memory in the studied mouse models.

Conclusions:

• Dyrk1a dysregulation is a common feature across various ADRDs.
• Dyrk1a inhibition via DYR533 demonstrates significant therapeutic potential for treating core pathologies and cognitive impairments in ADRDs.